Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assessment of the Cardiovascular System III: Palpation01:27

Assessment of the Cardiovascular System III: Palpation

Palpation involves feeling the body to evaluate texture, size, consistency, and tenderness for assessing cardiovascular health. The following steps are organized in a head-to-toe order:
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Assessment of the Cardiovascular System II: Inspection01:29

Assessment of the Cardiovascular System II: Inspection

Inspection is the initial step in assessing the cardiovascular system. It involves a detailed visual examination that provides crucial information about a patient's circulatory and cardiac health. This systematic process, conducted from head to toe, helps identify signs of cardiovascular conditions by observing physical appearance, skin and mucous membranes, jugular and carotid pulsations, chest symmetry, and the condition of the extremities.
Head and Neck
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Cardiovascular System Abnormal Findings I: Inspection and Palpation01:29

Cardiovascular System Abnormal Findings I: Inspection and Palpation

In a cardiovascular examination, inspection and palpation are crucial for identifying abnormalities.
Abnormal findings observed during an inspection

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in SSc-related RP.

Rheumatology (Oxford, England)·2025
Same author

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.

Rheumatology (Oxford, England)·2022
Same author

Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Arthritis & rheumatology (Hoboken, N.J.)·2022
Same author

Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.

Autoimmunity reviews·2021
Same author

Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.

Annals of the rheumatic diseases·2020
Same author

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.

The Journal of rheumatology·2020

Related Experiment Video

Updated: Jun 7, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Vascular alterations and sexual function in systemic sclerosis.

Ann Julie Impens1, James R Seibold

  • 1Scleroderma Program, University of Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA.

International Journal of Rheumatology
|October 29, 2010
PubMed
Summary

Sexual dysfunction, including male erectile dysfunction and female sexual arousal disorder, is prevalent in systemic sclerosis (SSc). Vasculopathy is a key factor, with phosphodiesterase type V inhibitors showing promise for men with SSc-related erectile dysfunction.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 7, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

Area of Science:

  • Rheumatology
  • Urology
  • Sexual Medicine

Background:

  • Sexual dysfunction is a frequent complication in systemic sclerosis (SSc).
  • Male erectile dysfunction (MED) affects approximately 80% of male SSc patients.
  • Over half of female SSc patients meet criteria for female sexual arousal disorder (FSAD).

Purpose of the Study:

  • To explore the prevalence and underlying mechanisms of sexual dysfunction in systemic sclerosis.
  • To evaluate the role of vasculopathy in sexual dysfunction in SSc patients.
  • To assess the efficacy of phosphodiesterase type V inhibitors in treating SSc-related sexual dysfunction.

Main Methods:

  • Review of existing literature on sexual dysfunction in systemic sclerosis.
  • Analysis of data regarding the prevalence of MED and FSAD in SSc cohorts.
  • Evaluation of treatment outcomes for phosphodiesterase type V inhibitors in SSc patients with sexual dysfunction.

Main Results:

  • Vasculopathy is strongly implicated in male erectile dysfunction in SSc.
  • The role of vasculopathy in female sexual dysfunction in SSc is less understood.
  • Phosphodiesterase type V inhibitors are effective for MED in SSc, with limited and inconsistent effects reported for female sexual dysfunction.

Conclusions:

  • Sexual dysfunction is a significant issue in systemic sclerosis, primarily linked to vasculopathy.
  • While effective for male patients, current treatments show inconsistent results for female sexual dysfunction in SSc.
  • Further research is needed to clarify the mechanisms and optimize treatment for female sexual dysfunction in SSc.